How to Help Patients Manage Their Dyslipidemia: A Primary Care Physician—Pharmacist Team Intervention

Huser MA Evans TS Berger V . Medication adherence trends with statins. Adv Ther 2005;22 (2):163–71.

Jackevicius CA Mamdani M Tu JV . Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288(4):462–7.

Perreault S Blais L Lamarre D Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005;59(5):564–73.

Catalan VS LeLorier J . Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3(6):417–26.

Simons LA Levis G Simons J . Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208–11.

Pearson TA . The undertreatment of LDL-cholesterol: addressing the challenge. Int J Cardiol 2000;74 Suppl 1:S23–8.

O'sMeara JG Kardia SL Armon JJ Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 2004;164(12):1313–8.

Pearson TA Laurora I Chu H The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160(4):459–67.

Marcelino JJ Feingold KR . Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996;100(6):605–10.

Tsuyuki RT Johnson JA Teo KK A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162(10):1149–55.

Tsuyuki RT Olson KL Dubyk AM Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Am J Med 2004;116(2):130–3.

Ellis SL Carter BL Malone DC Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000;20(12):1508–16.

Malone DC Carter BL Billups SJ An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Impact of Managed Pharmaceutical Care Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000;20(10):1149–58.

Geber J Parra D Beckey NP Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy 2002;22(6):738–47.

Bozovich M Rubino CM Edmunds J . Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000;20(11):1375–83.

Till LT Voris JC Horst JB . Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. J Manag Care Pharm 2003;9(3):269–73.

Rehring T F Stolcpart RS Sandhoff BG Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. J Vasc Surg 2006;43(6):1205–10.

Assemblée Nationale du Québec. Loi modifiant le Code des professions et d'sautres dispositions législatives dans le domaine de la santé. Available: www2.publicationsduquebec.gouv.qc.ca/dynamicSearch/telecharge.php?type=5&file=2002C33F.PDF (accessed July 15, 2007).

Villeneuve J Genest JJ Lamarre D Randomized controlled trial to evaluate an ambulatory integrated primary care management program for patients with dyslipidemia: TEAM study. Can Pharm J 2004;137(5):33.

Grumbach K Bodenheimer T . Can health care teams improve primary care practice? JAMA 2004;291(10):1246–51.

Lalonde L O'sConnor AM Drake E Development and pre-testing of a patient decision aid to assist pharmaceutical care in the prevention of cardiovascular disease. Pharmacotherapy 2004;24(7):909–22.

Lalonde L O'sConnor AM Duguay P Evaluation of a decision and risk profile in community pharmacy for patients considering options to improve cardiovascular health: the OPTIONS pilot study. Int J Pharm Pract 2006;14(1):51–62.

Ottawa Health Research Institute. Patient decision aids. Available: www.ohri.ca/decisionaid (accessed July 15, 2007).

O'sConnor AM Stacey D Entwistle V Decision aid for people facing health treatment or screening decisions (Cochrane review). In: The Cochrane Library, Issue 2. Oxford: Update Software; 2003.

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486–97.

Genest J Frohlich J Fodor G Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003;169(9):921–4.

McPherson R Frohlich J Fodor G Canadian Cardiovascular Society position statement — recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22(11): 913–27.

Villeneuve J Genest J Lamarre D . Impact of a dyslipidemia management workshop on community pharmacists's knowledge: TEAM workshop. Can Pharm J 2007;140(1):31.